Table 4 Analysis of clinical outcomes for all culture confirmed gram positive infections and the MRSA infection subset
From: Optimization of time to initial vancomycin target trough improves clinical outcomes
Outcome | Univariate | Multivariate | |||
|---|---|---|---|---|---|
TDM | CTRL | P-value | TDM vs. CTRL | P-value | |
Median (IQR) | Median (IQR) | Hazard Ratio (95% CI) | |||
All gram positive infections | |||||
Inpatient length of stay (days) | 7 (3,10) | 14 (8,26) | 0.03 | 1.41 (1.08–1.83) | 0.01 |
Inpatient length of VAN Treatment (days) | 4 (2,4) | 7 (5,10) | <0.001 | 1.5 (1.15–1.95) | 0.003 |
Time to clinical stability (days) | 4 (3,5) | 8 (3,7) | 0.004 | 1.51 (1.08–2.11) | 0.02 |
Time to normal WBC count (days) | 4 (2,10) | 6 (3,13) | 0.14 | ||
MRSA Subset | |||||
Inpatient length of stay (days) | 7 (4,20) | 16 (7,38) | 0.035 | 1.89 (1.08–3.3) | 0.03 |
Inpatient length of VAN treatment (days) | 5 (3,12) | 8 (5,16) | 0.034 | 2.52 (1.38–4.6) | 0.003 |
Time to clinical stability (days) | 4 (3,4) | 6 (4,10) | 0.013 | 2.69 (1.27–5.7) | 0.01 |
Time to normal WBC count (days) | 4 (2,5) | 5 (2,6) | 0.617 | ||